Camp4 Therapeutics Files 8-K on Officer/Director Changes
Ticker: CAMP · Form: 8-K · Filed: Mar 24, 2026 · CIK: 0001736730
Complexity: simple
Sentiment: neutral
Topics: executive-change, corporate-governance, 8-K
TL;DR
**Camp4 Therapeutics just filed an 8-K about leadership changes, watch for details.**
AI Summary
Camp4 Therapeutics Corp filed an 8-K on March 24, 2026, reporting an event that occurred on March 18, 2026, under Item 5.02, which typically covers changes in directors or officers and their compensation. While the specific details of the departure or appointment are not provided in this summary, this filing indicates a significant change in the company's leadership or executive compensation structure. This matters to investors because changes in key personnel can impact a company's strategic direction, operational stability, and future performance, potentially affecting stock valuation.
Why It Matters
Changes in leadership or executive compensation can signal shifts in company strategy or financial health, directly influencing investor confidence and stock price.
Risk Assessment
Risk Level: medium — Without specific details on who departed or was appointed, and their compensation, the impact on the company's future is uncertain, posing a medium risk.
Analyst Insight
A smart investor would monitor for subsequent filings or press releases from Camp4 Therapeutics Corp that provide specific names and details regarding the changes in directors, officers, or compensatory arrangements, as these specifics will determine the actual impact.
Key Players & Entities
- Camp4 Therapeutics Corp (company) — the filer of the 8-K
- 0001736730 (company) — CIK of Camp4 Therapeutics Corp
- 2026-03-18 (date) — period of report for the event
- 2026-03-24 (date) — filing and acceptance date of the 8-K
FAQ
What specific event did Camp4 Therapeutics Corp report in this 8-K filing?
Camp4 Therapeutics Corp reported an event under Item 5.02, which pertains to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
When did the event described in the 8-K filing occur?
The event described in the 8-K filing occurred on March 18, 2026, as indicated by the 'Period of Report'.
Filing Stats: 961 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2026-03-24 07:02:55
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CAMP The Nasdaq Global Market
- $120,000 — with the Company in an amount exceeding $120,000 since the beginning of the Company's la
Filing Documents
- camp-20260318.htm (8-K) — 29KB
- 0001736730-26-000021.txt ( ) — 153KB
- camp-20260318.xsd (EX-101.SCH) — 2KB
- camp-20260318_lab.xml (EX-101.LAB) — 24KB
- camp-20260318_pre.xml (EX-101.PRE) — 14KB
- camp-20260318_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Josh Mandel-Brehm Name: Josh Mandel-Brehm Title: President and Chief Executive Officer Date: March 24, 2026